SciSparc to Acquire Endoscope Patent Portfolio, Issuing 19.99% Equity for Entry into Multi-Billion Dollar Market
SPRC sits 20% above its 52-week low of $1 on elevated volume (20× avg).
Summary
SciSparc Ltd. is acquiring a portfolio of endoscope patents and intellectual property from Xylo Technologies Ltd. in exchange for 19.99% of its equity, marking a strategic entry into the multi-billion dollar GERD device market.
Key Events · M&A and Partnerships · SPRC
-
Strategic Asset Acquisition
SciSparc will acquire Xylo Technologies' complete portfolio of patents, trademarks, and intellectual property for innovative endoscopic systems, including the MUSE™ system.
-
Significant Equity Consideration
SciSparc will issue shares representing 19.99% of its outstanding share capital to Xylo as consideration, with an option for pre-funded warrants.
-
Entry into New Market
The acquisition positions SciSparc to enter the multi-billion dollar gastroesophageal reflux disease (GERD) device market.
-
Commercialization Plans
SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing, aiming to replicate Xylo's successful licensing model in new high-growth territories.
Analysis · SPRC · Life Sciences
SciSparc Ltd. is making a significant strategic move by acquiring a comprehensive portfolio of patents and intellectual property related to innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition, which involves issuing 19.99% of SciSparc's outstanding share capital, positions the company to enter the multi-billion dollar GERD device market. The substantial equity consideration represents significant dilution for existing shareholders, but the company aims for immediate commercialization and revenue generation by replicating a previously successful licensing model in new territories. This transaction could fundamentally alter SciSparc's business focus and growth trajectory.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRC was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $1.00 to $19.09. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.